Temperature control
All peptide pen orders are securely packed in thermally insulated packaging to help reduce temperature fluctuations during transport. Our MSSPT formulation approach is designed to support peptide stability during transport and storage. After delivery, follow the storage conditions stated for your pen.
MSSPT technology
MSSPT is ADRIA’s formulation approach for liquid peptide research materials. It brings together buffer and stabilizer selection with attention to light, oxidation, transport and storage conditions.
Performance depends on the specific compound, formulation and cartridge. Product-specific stability duration is not established by general ingredient studies.
Longevity and Anti-aging Research
SS-31 Pen
Low stock
Order within — to ship today
Arrives 26 – 30 Nov. to Europe
SS-31 Pen
Original price was: 400,00 €.340,00 €Current price is: 340,00 €.
The ADRIA SS-31 Pen presents SS-31 in a pre-reconstituted cartridge format for laboratory research. SS-31 (Elamipretide) is a synthetic tetrapeptide designed to support mitochondrial function. It selectively binds to cardiolipin in the inner mitochondrial membrane, thereby stabilizing mitochondrial structure and optimizing cellular energy (ATP) production. It is being investigated in the context of therapies for heart failure, mitochondrial diseases, and neurodegenerative conditions.
Compound information
Specifications
Molecular profile
- Sequence
- D-Arg-2,6-dimethylTyr-Lys-Phe-NH2
- Molecular mass
- 639.8 g/mol
- CAS number
- 736992-21-5
- Molecular formula
- C32H49N9O5
Material record
- Physical appearance
- Pre-mixed solution in a cartridge (planned pen format).
- Solubility
- Pre-reconstituted format; no reconstitution required.
- Product note
- Mitochondria-targeting tetrapeptide; studied for cardiolipin interaction, oxidative-stress pathway models, and cellular energy biology; supplied strictly for research use only.
Research overview
SS-31 Pen
Why this pen is perfect for research
- No preparation required
- Fully pre-formulated and ready. No mixing, no vials, no risk of mistakes.
- Extremely easy to handle
- Simply turn the dial to set your amount. Ideal for researchers with no prior experience using traditional peptides.
- Clean and safe workflow
- The closed pen system keeps everything hygienic and sterile and eliminates spills or contamination.
- Precise and consistent dosing
- The built-in scale ensures accurate measurements
- Reliable, stable quality
- Every application delivers the same concentration, supporting reproducible research results.
Description of SS-31
SS-31, also known as the Szeto-Schiller (SS) peptide, is an innovative synthetic tetrapeptide developed around the year 2000 by scientists Hazel H. Szeto and Peter W. Schiller. Initially designed as a ligand for the μ-opioid receptor, it unexpectedly demonstrated a remarkable ability to selectively accumulate in mitochondria, where it interacts with the phospholipid cardiolipin in the inner mitochondrial membrane. This interaction stabilizes mitochondrial structure, influences efficient ATP production, and concurrently reduces the formation of reactive oxygen species (ROS), which are key contributors to cellular damage and aging. Due to its small molecular size and lipophilic properties, SS-31 readily crosses cellular and organelle membranes, allowing it to efficiently target mitochondria across diverse tissue types.
Mitochondrial dysfunction, often linked to the degradation or destabilization of cardiolipin, underlies a wide range of chronic and degenerative diseases, including neurodegenerative disorders (e.g., Alzheimer's and Parkinson's diseases), metabolic syndromes, cancer, cardiomyopathies, and mitochondrial myopathies. SS-31 is currently undergoing clinical trials as a research compound in the context of heart failure, primary mitochondrial myopathy, and other mitochondrial disorders. Recent research using chemical cross-linking and mass spectrometry has revealed that SS-31 interacts with multiple key mitochondrial proteins involved in oxidative phosphorylation and 2-oxoglutarate metabolism, further supporting its potential as a targeted mitochondrial research compound.
Overview of Published Research
Primary mitochondrial diseases (PMDs) are a group of genetically determined disorders caused by dysfunction of the mitochondrial apparatus, which is responsible for the production of cellular energy in the form of ATP. These conditions primarily affect organ systems with high energy demands, such as skeletal muscle, the heart, nervous system, and kidneys. SS-31 (Elamipretide) is a mitochondria-targeted synthetic tetrapeptide that interacts with cardiolipin in the inner mitochondrial membrane, thereby stabilizing mitochondrial structure, reducing oxidative stress, and influencing ATP synthesis function. Initial preclinical evidence of SS-31's activity emerged from animal studies involving ischemia-reperfusion injury, where treatment was associated with accelerated ATP recovery, reduced necrosis and apoptosis, and changes in tissue function.
Important insights have also come from experiments investigating the effects of SS-31 on aging skeletal muscle. In older mice, a single dose of SS-31 led to changes in mitochondrial bioenergetics, reflected by increased ATP production, improved phosphorylation efficiency (P/O ratio), and enhanced cellular energy status. These effects were not observed in younger animals, suggesting a specific action of the tetrapeptide on age-related mitochondrial deficits. Moreover, SS-31 reduced redox stress, mitochondrial H₂O₂ emission, and influenced muscle fatigue resistance, resulting in increased physical endurance after 8 days of administration. These findings support its research potential in the context of sarcopenia and other forms of age-related mitochondrial dysfunction.
SS-31 has also demonstrated activity in research into kidney injury resulting from ischemia-reperfusion (I/R) stress, where rapid reactivation of mitochondrial function during the early phase of reperfusion is critical for the survival of tubular cells. The peptide inhibits the opening of the mitochondrial permeability transition (MPT) pore, thereby preventing mitochondrial depolarization, reducing ROS production, and attenuating inflammation. These multifactorial effects highlight its research potential not only for genetically driven mitochondrial diseases but also for acute and age-related mitochondrial dysfunctions.
Ischemia induces acute kidney injury (AKI) primarily due to ATP depletion, and rapid ATP recovery upon reperfusion is essential to minimize tissue damage. This recovery process is often impaired by the destruction of mitochondrial cristae, which are essential for efficient ATP synthesis. SS-31 binds with high affinity to cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and preventing cardiolipin peroxidation through inhibition of cytochrome c peroxidase activity. The resulting effects include mitochondrial protection during ischemia, accelerated ATP restoration following reperfusion, recovery of the actin cytoskeleton and cell polarity, inhibition of apoptosis, and an overall reduction in renal dysfunction. These mechanisms affirm SS-31's potential as a promising research candidate in the context of ischemia-reperfusion injury, which is currently being evaluated in clinical trials.
Although phase III clinical trials with the peptide SS-31 did not yield conclusive results, earlier phase II studies demonstrated encouraging signs of changes in physical performance in subjects with primary mitochondrial myopathy (PMM) after only five days of administration, without serious adverse effects. The peptide acts specifically on cardiolipin—an essential phospholipid of the mitochondrial membrane—stabilizing it and protecting it from oxidative damage, thereby potentially influencing mitochondrial function.
While the phase III study failed to meet its predefined primary endpoints (e.g., improvement in 6-minute walk distance and fatigue), the compound's safety profile remains favorable. Researchers and experts, such as Dr. Bruce Cohen, have suggested that the selected endpoints may not have been appropriate and that further investigations may reveal the research potential of elamipretide not only for PMM but also for other mitochondrial diseases, including Barth syndrome and age-related macular degeneration.
Currently, SS-31 is considered one of the few promising research candidates in the context of mitochondrial disorders. Ongoing research is being conducted through additional clinical trials involving new indications, extended durations, and alternative activity endpoints. In parallel, derivatives of SS-31 and other mitochondria-targeted molecules are also being investigated, fostering interest in whether significant advances in the research into mitochondrial dysfunctions may be achieved in the near future.
Mitochondrial dysfunction represents a key pathological component in heart failure and ischemia-reperfusion injury of the myocardium. The peptide SS-31 has emerged as a promising research compound capable of selectively targeting mitochondrial function, primarily through its interaction with cardiolipin. Studies on human cardiac tissue have demonstrated that SS-31 can influence mitochondrial oxygen flux and respiratory complex activity without requiring cardiolipin remodeling, suggesting the involvement of multiple mechanisms of action. These findings support the broader investigation of SS-31 in the context of mitochondrial dysfunction associated with cardiovascular diseases.
Animal model experiments, specifically in dogs with advanced heart failure, have confirmed the observed effects of chronic SS-31 administration on left ventricular function and mitochondrial ATP production. This correlation suggests that SS-31 may contribute to research into myocardial energy balance and cardiac tissue remodeling. Moreover, the peptide has also shown activity in acute settings, demonstrating the ability to reduce levels of HtrA2—a protease released from mitochondria during apoptosis, which is characteristic of ischemia-reperfusion injury.
Clinical and preclinical evidence indicates that SS-31 holds potential as a research compound in the context of both acute and chronic mitochondrial injury in cardiovascular diseases. In cases of ST-elevation myocardial infarction (STEMI), it has been shown to influence mitochondrial apoptosis, thereby affecting cardiomyocyte viability. These findings support the growing research interest in mitochondria as a target, with SS-31 emerging as one of the most promising candidates for further investigation in the context of myocardial ischemia.
Mitochondrial damage has emerged as a key factor in the pathogenesis of type 2 diabetes, with oxidative stress playing a central role in the development of complications such as microvascular disease. SS-31, a mitochondria-targeted peptide, has demonstrated activity in reducing the production of reactive oxygen species (ROS) associated with mitochondrial dysfunction in diabetes. Studies in both human and animal models have shown that SS-31 administration reduces oxidative damage, influences mitochondrial membrane potential, and increases levels of SIRT1, which are associated with insulin sensitivity. These effects suggest that SS-31 may be of research interest in the context of diabetic complications, including microvascular disease.
Further research indicates that SS-31 exerts effects relevant to oxidative stress and inflammation in subjects with type 2 diabetes mellitus, with potential relevance to cardiovascular risk—a common complication of this condition. Administration of SS-31 was found to reduce levels of pro-inflammatory markers such as NFκB-p65 and TNFα, while also influencing interactions between leukocytes and endothelial cells. These findings support the hypothesis that SS-31 may be of interest in research into mitochondrial function and inflammatory processes frequently associated with long-term diabetic complications, particularly in the context of cardiovascular health.
SS-31 has emerged as a subject of research interest in the context of chronic inflammation, primarily through its impact on mitochondrial oxidative stress. This tetrapeptide demonstrates the ability to scavenge reactive oxygen species (ROS), thereby influencing the initiation of intracellular inflammatory cascades. Studies conducted on cell cultures and animal models have confirmed that SS-31 influences inflammatory pathways by downregulating the expression of proteins such as CD36, FIS1, and NF-κB p65, which are known to act as key triggers of inflammation. For instance, the suppression of FIS1—a regulator of mitochondrial fission—helps maintain mitochondrial integrity and influences activation of the inflammasome, a process frequently responsible for eliciting inflammatory responses. Additionally, SS-31 stabilizes mitochondrial morphology, exerting a protective effect particularly in neuroinflammatory conditions such as Alzheimer's disease or CNS injury during sepsis.
Another important property of SS-31 is its ability to suppress the activity of ROS-producing enzymes such as NADPH oxidase, while simultaneously influencing the expression of antioxidant defense mechanisms, including MnSOD and catalase. These effects result in reduced levels of pro-inflammatory cytokines such as TNF-α and suppression of the transcription factor NF-κB, which plays a central role in chronic inflammation. Furthermore, administration of SS-31 has been associated with decreased tissue damage and improved histological parameters, for example in the kidneys of diabetic mice, indicating its potential research interest in the context of inflammatory complications in chronic diseases. These findings support the investigation of SS-31 as a research compound with broad-spectrum anti-inflammatory effects, grounded in mitochondrial protection and restoration of cellular homeostasis.
For laboratory purposes and personal observation only. Not for human consumption.
Research material handling
Transport and storage
Pre-mixed pen format
Peptide pens are supplied as a pre-mixed solution in a cartridge. No reconstitution is required.
Temperature-controlled transport
The supplied handling specification calls for insulated, temperature-controlled packaging. The approved transit range and permitted temperature excursions must be confirmed for the finished formulation.
Storage of reconstituted peptides
Peptide pens come pre-reconstituted and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Tests
Documentation is available on request
Contact us for the current record for this strength. We never substitute a generic or mismatched certificate.
Your batch is confirmed when your order is allocated.Source record
References
Juan D. Chavez, Xiaoting Tang, Matthew D. Campbell, James E. Bruce, „Mitochondrial protein interaction landscape of SS-31", 2020.
H. H. Szeto et al., "Mitochondria-Targeted Peptide Accelerates ATP Recovery and Reduces Ischemic Kidney Injury," J. Am. Soc. Nephrol. JASN, vol. 22, no. 6, pp. 1041–1052, Jun. 2011, doi: 10.1681/ASN.2010080808.
M. P. Siegel et al., "Mitochondrial targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice," Aging Cell, vol. 12, no. 5, pp. 763–771, Oct. 2013, doi: 10.1111/acel.12102.
A. V. Birk et al., "The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin," J. Am. Soc. Nephrol. JASN, vol. 24, no. 8, pp. 1250–1261, Jul. 2013, doi: 10.1681/ASN.2012121216.
K. C. Chatfield et al., "Elamipretide Improves Mitochondrial Function in the Failing Human Heart," JACC Basic Transl. Sci., vol. 4, no. 2, pp. 147–157, Apr. 2019, doi: 10.1016/j.jacbts.2018.12.005.
A. Karaa, R. Haas, A. Goldstein, J. Vockley, W. D. Weaver, and B. H. Cohen, "Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy," Neurology, vol. 90, no. 14, pp. e1212–e1221, Apr. 2018, doi: 10.1212/WNL.0000000000005255.
A. M. PhD, "Elamipretide Failed to Meet Promise of Earlier Trial Results for...," Mitochondrial Disease News, Jan. 10, 2020. https://mitochondrialdiseasenews.com/2020/01/10/elamipretide-failed-to-meet-promise-of-earlier-trial-results-for-primary-mitochondrial-myopathy-data-show/ (accessed Apr. 06, 2020).
"Could Elamipretide Become the First Treatment Option for Primary Mitochondrial Myopathy?," Neurology Live. https://www.neurologylive.com/clinical-focus/could-elamipretide-treatment-option-primary-mitochondrial-myopathy (accessed Apr. 06, 2020).
H. N. Sabbah, R. C. Gupta, S. Kohli, M. Wang, S. Hachem, and K. Zhang, "Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure," Circ. Heart Fail., vol. 9, no. 2, p. e002206, Feb. 2016, doi: 10.1161/CIRCHEARTFAILURE.115.002206.
M. Hortmann et al., "The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction," Eur. Heart J. Acute Cardiovasc. Care, vol. 8, no. 8, pp. 695–702, Dec. 2019, doi: 10.1177/2048872617710789.
I. Escribano-Lopez et al., "The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes," Sci. Rep., vol. 8, no. 1, pp. 1–10, Oct. 2018, doi: 10.1038/s41598-018-34251-8.
Y. Mo et al., "SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1 expression in lipopolysaccharide-stimulated microglia," Biochem. Biophys. Res. Commun., vol. 520, no. 1, pp. 171–178, Nov. 2019, doi: 10.1016/j.bbrc.2019.09.077.
Y. Hou et al., "The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy," Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc., vol. 33, no. 11, pp. 1908–1918, 01 2018, doi: 10.1093/ndt/gfy021.
Y. Hou et al., "Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy," Am. J. Physiol.-Ren. Physiol., vol. 310, no. 6, pp. F547–F559, Dec. 2015, doi: 10.1152/ajprenal.00574.2014.
National Center for Biotechnology Information
PubChem Compound Summary: Elamipretide
Authoritative identity record for SS-31, also described as elamipretide.
PubChem View source ↗Zhao W, Xu Z, Cao J, et al. · 2019
Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
Primary experimental report using elamipretide/SS-31.
Journal of Neuroinflammation · 10.1186/s12974-019-1627-9 View source ↗Karaa A, Bertini E, Carelli V, et al. · 2023
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
Primary clinical research report for elamipretide.
Neurology · 10.1212/wnl.0000000000207402 View source ↗Juan D. Chavez, Xiaoting Tang, Matthew D. Campbell, James E. Bruce · 2020
Mitochondrial protein interaction landscape of SS-31
2020H. H. Szeto et al. · 2011
Mitochondria-Targeted Peptide Accelerates ATP Recovery and Reduces Ischemic Kidney Injury
J. Am. Soc. Nephrol. JASN · 10.1681/asn.2010080808 View source ↗M. P. Siegel et al. · 2013
Mitochondrial targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice
Aging Cell · 10.1111/acel.12102 View source ↗A. V. Birk et al. · 2013
The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin
J. Am. Soc. Nephrol. JASN · 10.1681/asn.2012121216 View source ↗K. C. Chatfield et al. · 2019
Elamipretide Improves Mitochondrial Function in the Failing Human Heart
JACC Basic Transl. Sci · 10.1016/j.jacbts.2018.12.005 View source ↗A. Karaa, R. Haas, A. Goldstein, J. Vockley, W. D. Weaver, and B. H. Cohen · 2018
Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
Neurology · 10.1212/wnl.0000000000005255 View source ↗A. M. PhD · 2020
Elamipretide Failed to Meet Promise of Earlier Trial Results for
Mitochondrial Disease News, Jan. 10· 2020
Could Elamipretide Become the First Treatment Option for Primary Mitochondrial Myopathy?
Neurology LiveH. N. Sabbah, R. C. Gupta, S. Kohli, M. Wang, S. Hachem, and K. Zhang · 2016
Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure
Circ. Heart Fail · 10.1161/circheartfailure.115.002206 View source ↗M. Hortmann et al. · 2019
The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction
Eur. Heart J. Acute Cardiovasc. Care · 10.1177/2048872617710789 View source ↗I. Escribano-Lopez et al. · 2018
The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes
Sci. Rep · 10.1038/s41598-018-34251-8 View source ↗Y. Mo et al. · 2019
SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1 expression in lipopolysaccharide-stimulated microglia
Biochem. Biophys. Res. Commun · 10.1016/j.bbrc.2019.09.077 View source ↗Y. Hou et al. · 1908
The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy
Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc · 10.1093/ndt/gfy021 View source ↗Y. Hou et al. · 2015
Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy
Am. J. Physiol.-Ren. Physiol · 10.1152/ajprenal.00574.2014 View source ↗Customer reviews
Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.
Read full review →More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.
Read full review →Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!
Read full review →Great service!
Read full review →Always on time and customer care is super great
Read full review →Fast good, and quality is perfect
Read full review →ordered 3 times now and everything ok every time.
Read full review →Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.
Read full review →Great quality product
Read full review →Everything was great, super customer support, honest, reliable
Read full review →Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products
Read full review →Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P
Read full review →



